DUBLIN–(BUSINESS WIRE)–The “Global Seasonal Influenza Vaccine Market (2023 Edition): Analysis By Vaccine Type (Inactivated, Live Attenuated), Valency (Quadrivalent, Trivalent), Age Group, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)” report has been added to ResearchAndMarkets.com’s offering.
The Global Seasonal Influenza Vaccine Market is poised to reach USD 9.3 Billion by 2029, a significant increase from the 2022 figure of USD 5.8 Billion. Over the forecast period from 2024 to 2029, the Global Seasonal Influenza Vaccines market is anticipated to grow at a steady CAGR of 7.61%.
This research report provides a comprehensive analysis of various regions, including the Americas, Europe, APAC, and the Middle East Africa, along with an in-depth examination of 10 countries, including the United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, Australia, and South Korea. The report encompasses essential data such as market size, annual growth, potential analysis, competitive assessments of market players, investment opportunities, and demand forecasts.
In addition to assessing growth drivers, the research report also considers factors such as limitations, supply and demand risks, and other crucial statistics. It offers a comprehensive evaluation of current and future market trends that are relevant to the evolution of the market.
Several factors contribute to the favorable growth of the Global Seasonal Influenza Vaccine market. These include changing weather conditions, the rapid transmission of respiratory diseases, increased awareness, and a growing demand for retail solutions. Influenza is a significant global health concern, leading to a substantial burden of illness, hospitalizations, and fatalities each year. According to the World Health Organization (WHO), an estimated 1 million people worldwide contract seasonal influenza annually, resulting in an estimated 290,000 to 650,000 deaths each year due to flu-related complications.
The global seasonal influenza vaccine market benefits from increased awareness about flu prevention, rising healthcare expenditure, and growing government initiatives to promote immunization programs.
Prevention and control of seasonal influenza primarily rely on annual vaccination. Each year, the flu vaccine is developed to protect against the most prevalent strains of the virus. Various types of influenza vaccines are available, with the most common being trivalent vaccines (protecting against three flu strains) and quadrivalent vaccines (protecting against four flu strains). These vaccines can be administered through injection (inactivated vaccine) or nasal spray (live attenuated vaccine).
Retail pharmacies play a crucial role in providing easy access to seasonal influenza vaccines for the general population. With numerous pharmacy locations in communities, individuals can conveniently receive their vaccinations without the need for appointments or visits to healthcare facilities, which can be more time-consuming and less accessible.
The adoption of digital technologies and tracking systems in the seasonal influenza vaccine market presents opportunities to enhance vaccine distribution, improve vaccination campaigns, ensure vaccine safety, and enable data-driven decision-making. By leveraging digital solutions, stakeholders can optimize vaccine delivery, increase vaccine uptake, and contribute to more effective influenza prevention and control efforts.
Scope of the Report
- The report analyses the Seasonal Influenza Vaccine Market by Value (USD Million)
- The report presents the analysis of Seasonal Influenza Vaccine Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029
- The report analyses the Seasonal Influenza Vaccine Market by Vaccine Type (Inactivated Influenza Vaccine (IIV), Live Attenuated Influenza Vaccine (LAIV))
- The report analyses the Seasonal Influenza Vaccine Market by Valency (Quadrivalent, Trivalent)
- The report analyses the Seasonal Influenza Vaccine Market by Age Group (Pediatrics, Adults, Elderly)
- The report analyses the Seasonal Influenza Vaccine Market by Distribution Channel (Hospitals, Pharmacies, Government Supply)
- The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users
- Also, the major opportunities, trends, drivers and challenges of the industry has been analyzed in the report
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
|No. of Pages||280|
|Forecast Period||2024 – 2029|
|Estimated Market Value (USD) in 2024||$6.5 Billion|
|Forecasted Market Value (USD) by 2029||$9.3 Billion|
|Compound Annual Growth Rate||7.6%|
- Leveraging digital technologies and tracking systems
- Improved vaccine distribution and access
Industry Ecosystem Analysis
- Macro-Economic Factor Assessment
- Porter Analysis
- Recommended Seasonal Influenza Vaccines for Different Age Groups
- Market Share of Prominent Companies
- Company Profiling
- CSL Seqirus
- AstraZeneca PLC
- Abbott Laboratories
- Sinovac Biotech
- Serum Institute of India
- Daiichi Sankyo
- Dalian Aleph Biomedical
For more information about this report visit https://www.researchandmarkets.com/r/ohoszz
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
The post Global Seasonal Influenza Vaccine Research Report 2023: Trivalent vs. Quadrivalent, Injection vs. Nasal Spray – Market Forecasts to 2029 – ResearchAndMarkets.com appeared first on Fintech News.